Research News and Research

RSS

Increase of alcohol taxes can reduce alcohol-related deaths

Adjusting the alcohol tax in Florida to account for inflation since 1983 would prevent 600 to 800 deaths each year in that state from diseases caused by chronic heavy alcohol use, according to a new study from the University of Florida. The Florida legislature last increased alcohol taxes in 1983.

10 Aug 2010

Healthy eggs require tremendous amount of zinc to reach maturity for fertilization: Research

Scientists as well as fertility doctors have long tried to figure out what makes a good egg that will produce a healthy embryo. It's a particularly critical question for fertility doctors deciding which eggs isolated from a woman will produce the best embryos and, ultimately, babies.New research reveals healthy eggs need a tremendous amount of zinc to reach maturity and be ready for fertilization,a finding that may ultimately help physicians assess the best eggs for fertility treatment, according to a study from Northwestern University.

10 Aug 2010

Australia ranks near top when it comes to alcohol abuse: Study

In a new study researchers have found that Australia ranks near the top when it comes to alcohol abuse. The study was conducted by the National Drug and Alcohol Research Centre (NDARC) and it found that one in five Australians has a drinking problem and four in five go untreated for these problems. Professor Maree Teesson and her team analyzed data collected from almost 9,000 Australians aged 16 to 85 years for the National Survey of Mental Health and Wellbeing in 2007.

9 Aug 2010

U.N. says nearly 14M Pakistanis affected by floods

On Monday the U.N. said that 13.8 million people have been affected by the floods in Pakistan as the death toll has now reached 1,600, Agence France-Presse reports.

9 Aug 2010

Insurers to help doctors, hospitals buy health IT

The Wall Street Journal: Health insurance companies are moving to help doctors and hospitals adopt electronic medical records with subsidies, bonuses for adoption and, in some cases, digital products to improve quality and disease management. "The lure: the estimated 80% of U.S. physicians and 90% of hospitals whose records are still on paper, and the $27 billion in federal stimulus money available to help these holdouts switch.

9 Aug 2010

Lentigen receives NIH SBIR grant for program on clinical vector for TCR immunotherapy targeted to melanoma

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) Small Business Innovation Research grant (SBIR) for a program on "Clinical Vector for TCR Immunotherapy Targeted to Melanoma". In this program, Lentigen will collaborate with Dr. Michael Nishimura, Professor of Surgery, at the Medical University of South Carolina (MUSC).

9 Aug 2010

Also in Global Health News: Food production and climate change; Poverty and hunger in India; Composting toilets in Malawi

A new discussion paper, led by a researcher from the University of Nairobi and produced by the International Food Policy Research Institute, examines how 10 sub-Saharan African countries have adapted food production to mitigate the effects of climate change, IRIN reports. The paper found that most countries use crops that mature faster and are tolerant of frequent and intense droughts.

9 Aug 2010

New familial link in juvenile myelomonocytic leukemia discovered

A UCSF-led team has discovered a direct link between an inherited genetic mutation, a set of developmental abnormalities and a rare form of childhood leukemia called juvenile myelomonocytic leukemia, or JMML. The study demonstrates a new familial link in JMML and has significant implications, the researchers say, for improving the diagnosis and treatment of the disease.

9 Aug 2010

Morphine plus oxycodone IV combination exhibits improved analgesia, tolerability compared to IV morphine

QRxPharma Limited announced today positive results of its Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of its IV (intravenous) formulation of morphine plus oxycodone versus IV morphine alone for the treatment of moderate to severe post-operative pain in patients following hip replacement surgery. The main findings demonstrated that QRxPharma's formulation of MoxDuo IV resulted in fewer side effects and offered better pain relief than morphine alone.

9 Aug 2010

FDA approves Pfizer's Prefilled Dual-Chamber Syringe for XYNTHA administration in hemophilia A patients

Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A.

9 Aug 2010

KHN column -- Senate dysfunction and health care cost control: In private sector we trust?

In his latest Kaiser Health New column, Austin Frakt writes: "There's good news and bad news. The good news is that if cost-saving provisions of the new health reform law work, Medicare solvency will be extended by 12 years, according to the program's trustees.

9 Aug 2010

Today's OpEds: U.S. vs. Nordic health care; Medicare solvency; Patients and health costs; Mystery of ACOs

Beginning, like the United States, with excellent intentions, [each of the Nordic countries'] health care system evolved similarly. Initially, all care was covered. But costs rose. The government covered fewer illnesses. Expensive treatments increased government spending. ... This is not an evolution that the U.S. can avoid (Mark B. Constantian, 8/8).

9 Aug 2010

Progenics second-quarter total revenue decreases to $2.3 million

Progenics Pharmaceuticals, Inc. today announced its results of operations for the second quarter and six months ended June 30, 2010.

9 Aug 2010

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and six months ended June 30, 2010 and provided a business update.

9 Aug 2010

CPEX reports $1.2M second-quarter net income vs $1.2M net loss year earlier

CPEX Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010. For the quarter CPEX reported revenues of $5.8 million and net income of $1.2 million.

9 Aug 2010

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.

9 Aug 2010

Clinical Data first-quarter gross revenue increases 52% to $6.2 million

Clinical Data, Inc. today announced operational and financial results for the first quarter ended June 30, 2010, noting key accomplishments including the acceptance of the Company's new drug application (NDA) for vilazodone by the U.S. Food and Drug Administration (FDA) and the successful completion of a public offering .

9 Aug 2010

Arcadia Resources first-quarter net revenues decrease to $25.8 million

Arcadia Resources, Inc., a leading provider of innovative consumer health care services under the Arcadia HealthCare(SM) brand, today announced fiscal 2011 first quarter net revenues of $25.8 million and a net loss of $4.0 million, or $0.02 per share, which compares to net revenue of $26.4 million and a net loss of $4.6 million, or $0.03 per share for the same period in the fiscal 2010.

9 Aug 2010

GTx second-quarter net loss increases to $12.9 million

GTx, Inc. today reported financial results for the second quarter of 2010. The net loss for the quarter ended June 30, 2010 was $12.9 million compared with a net loss of $11.3 million for the quarter ended June 30, 2009. The net loss for the second quarter of 2010 included a $1.7 million non-cash impairment charge related to the conclusion of the Phase III clinical trial of toremifene 20 mg.

9 Aug 2010

Millennium Laboratories signs agreement to assist physicians with drug monitoring services, tools

Millennium Laboratories, Inc., a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain, announced today a national agreement with MultiPlan, the nation's leading comprehensive provider of healthcare cost management solutions. As a participating provider in the PHCS and MultiPlan Networks, Millennium Laboratories will assist participating physicians with state-of-the-art therapeutic drug monitoring services and tools.

9 Aug 2010

Research News and Research

Increase of alcohol taxes can reduce alcohol-related deaths

Healthy eggs require tremendous amount of zinc to reach maturity for fertilization: Research

Australia ranks near top when it comes to alcohol abuse: Study

U.N. says nearly 14M Pakistanis affected by floods

Insurers to help doctors, hospitals buy health IT

Lentigen receives NIH SBIR grant for program on clinical vector for TCR immunotherapy targeted to melanoma

Also in Global Health News: Food production and climate change; Poverty and hunger in India; Composting toilets in Malawi

New familial link in juvenile myelomonocytic leukemia discovered

Morphine plus oxycodone IV combination exhibits improved analgesia, tolerability compared to IV morphine

FDA approves Pfizer's Prefilled Dual-Chamber Syringe for XYNTHA administration in hemophilia A patients

KHN column -- Senate dysfunction and health care cost control: In private sector we trust?

Today's OpEds: U.S. vs. Nordic health care; Medicare solvency; Patients and health costs; Mystery of ACOs

Progenics second-quarter total revenue decreases to $2.3 million

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

CPEX reports $1.2M second-quarter net income vs $1.2M net loss year earlier

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Clinical Data first-quarter gross revenue increases 52% to $6.2 million

Arcadia Resources first-quarter net revenues decrease to $25.8 million

GTx second-quarter net loss increases to $12.9 million

Millennium Laboratories signs agreement to assist physicians with drug monitoring services, tools

Spectroscopy Applications in the Environment eBook eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence